Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer

Por Kosuke Hashimoto, Kyoichi Kaira, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu, Ichiei Kuji
Publicado em 2020-03-01

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer

Por Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Publicado em 2022-05-01

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients

Por Ayako Shiono, Kyoichi Kaira, Atsuto Mouri, Ou Yamaguchi, Kosuke Hashimoto, Takahiro Uchida, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu
Publicado em 2019-04-01

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

Por Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri, Yu Miura, Ayako Shiono, Fuyumi Nishihara, Yoshitake Murayama, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu
Publicado em 2019-04-01